184 related articles for article (PubMed ID: 16914390)
1. Heart positive: design of a randomized controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia.
Samson SL; Pownall HJ; Scott LW; Ballantyne CM; Smith EO; Sekhar RV; Balasubramanyam A
Contemp Clin Trials; 2006 Dec; 27(6):518-30. PubMed ID: 16914390
[TBL] [Abstract][Full Text] [Related]
2. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial.
Balasubramanyam A; Coraza I; Smith EO; Scott LW; Patel P; Iyer D; Taylor AA; Giordano TP; Sekhar RV; Clark P; Cuevas-Sanchez E; Kamble S; Ballantyne CM; Pownall HJ
J Clin Endocrinol Metab; 2011 Jul; 96(7):2236-47. PubMed ID: 21565796
[TBL] [Abstract][Full Text] [Related]
3. Intensive lifestyle modification reduces Lp-PLA2 in dyslipidemic HIV/HAART patients.
Wooten JS; Nambi P; Gillard BK; Pownall HJ; Coraza I; Scott LW; Nambi V; Ballantyne CM; Balasubramanyam A
Med Sci Sports Exerc; 2013 Jun; 45(6):1043-50. PubMed ID: 23299761
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.
Franceschini G; Favari E; Calabresi L; Simonelli S; Bondioli A; Adorni MP; Zimetti F; Gomaraschi M; Coutant K; Rossomanno S; Niesor EJ; Bernini F; Benghozi R
J Clin Lipidol; 2013; 7(5):414-22. PubMed ID: 24079282
[TBL] [Abstract][Full Text] [Related]
5. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy.
Lee JH; Chan JL; Sourlas E; Raptopoulos V; Mantzoros CS
J Clin Endocrinol Metab; 2006 Jul; 91(7):2605-11. PubMed ID: 16636130
[TBL] [Abstract][Full Text] [Related]
6. Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults.
Badiou S; Merle De Boever C; Dupuy AM; Baillat V; Cristol JP; Reynes J
Atherosclerosis; 2004 Feb; 172(2):273-9. PubMed ID: 15019537
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087.
Aberg JA; Zackin RA; Brobst SW; Evans SR; Alston BL; Henry WK; Glesby MJ; Torriani FJ; Yang Y; Owens SI; Fichtenbaum CJ;
AIDS Res Hum Retroviruses; 2005 Sep; 21(9):757-67. PubMed ID: 16218799
[TBL] [Abstract][Full Text] [Related]
8. Effects of high-intensity endurance and resistance exercise on HIV metabolic abnormalities: a pilot study.
Robinson FP; Quinn LT; Rimmer JH
Biol Res Nurs; 2007 Jan; 8(3):177-85. PubMed ID: 17172316
[TBL] [Abstract][Full Text] [Related]
9. Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy.
Gerber MT; Mondy KE; Yarasheski KE; Drechsler H; Claxton S; Stoneman J; DeMarco D; Powderly WG; Tebas P
Clin Infect Dis; 2004 Aug; 39(3):419-25. PubMed ID: 15307011
[TBL] [Abstract][Full Text] [Related]
10. [Adipokines and highly active antiretroviral therapy related lipodystrophy: clinical study of 52 cases].
Tao MM; Zhang L; Qiu ZF; Xie J; Han Y; Yu W; Li M; Li TS
Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):867-71. PubMed ID: 19671283
[TBL] [Abstract][Full Text] [Related]
11. Exercise training in HIV-1-infected individuals with dyslipidemia and lipodystrophy.
Terry L; Sprinz E; Stein R; Medeiros NB; Oliveira J; Ribeiro JP
Med Sci Sports Exerc; 2006 Mar; 38(3):411-7. PubMed ID: 16540826
[TBL] [Abstract][Full Text] [Related]
12. Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy.
Addy CL; Gavrila A; Tsiodras S; Brodovicz K; Karchmer AW; Mantzoros CS
J Clin Endocrinol Metab; 2003 Feb; 88(2):627-36. PubMed ID: 12574192
[TBL] [Abstract][Full Text] [Related]
13. Combination of dietary phytosterols plus niacin or fenofibrate: effects on lipid profile and atherosclerosis in apo E-KO mice.
Yeganeh B; Moshtaghi-Kashanian GR; Declercq V; Moghadasian MH
J Nutr Biochem; 2005 Apr; 16(4):222-8. PubMed ID: 15808326
[TBL] [Abstract][Full Text] [Related]
14. Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy: a model of 'systemic steatosis'.
Balasubramanyam A; Sekhar RV; Jahoor F; Jones PH; Pownall HJ
Curr Opin Lipidol; 2004 Feb; 15(1):59-67. PubMed ID: 15166810
[TBL] [Abstract][Full Text] [Related]
15. Visceral fat as target of highly active antiretroviral therapy-associated metabolic syndrome.
Barbaro G
Curr Pharm Des; 2007; 13(21):2208-13. PubMed ID: 17627554
[TBL] [Abstract][Full Text] [Related]
16. Rosiglitazone in the treatment of HAART-associated lipodystrophy--a randomized double-blind placebo-controlled study.
Sutinen J; Häkkinen AM; Westerbacka J; Seppälä-Lindroos A; Vehkavaara S; Halavaara J; Järvinen A; Ristola M; Yki-Järvinen H
Antivir Ther; 2003 Jun; 8(3):199-207. PubMed ID: 12924536
[TBL] [Abstract][Full Text] [Related]
17. Dyslipidemia in visceral obesity: mechanisms, implications, and therapy.
Chan DC; Barrett HP; Watts GF
Am J Cardiovasc Drugs; 2004; 4(4):227-46. PubMed ID: 15285698
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A
Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343
[TBL] [Abstract][Full Text] [Related]
19. The high-fat high-fructose hamster as an animal model for niacin's biological activities in humans.
Connolly BA; O'Connell DP; Lamon-Fava S; LeBlanc DF; Kuang YL; Schaefer EJ; Coppage AL; Benedict CR; Kiritsy CP; Bachovchin WW
Metabolism; 2013 Dec; 62(12):1840-9. PubMed ID: 24035454
[TBL] [Abstract][Full Text] [Related]
20. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
